StockNews.com assumed coverage on shares of iCAD (NASDAQ:ICAD - Free Report) in a research report released on Saturday morning. The firm issued a sell rating on the technology company's stock.
Several other research firms have also issued reports on ICAD. BTIG Research lowered iCAD from a "buy" rating to a "neutral" rating in a research note on Wednesday, April 16th. Laidlaw reiterated a "hold" rating on shares of iCAD in a research report on Thursday, April 17th. Finally, Craig Hallum lowered shares of iCAD from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 16th.
View Our Latest Research Report on iCAD
iCAD Price Performance
Shares of ICAD traded up $0.09 on Friday, reaching $3.42. 715,380 shares of the stock traded hands, compared to its average volume of 375,072. The stock's 50-day moving average price is $2.34 and its 200-day moving average price is $2.22. The firm has a market cap of $93.59 million, a price-to-earnings ratio of -26.31 and a beta of 1.78. iCAD has a 12 month low of $1.18 and a 12 month high of $3.78.
iCAD (NASDAQ:ICAD - Get Free Report) last announced its quarterly earnings results on Wednesday, March 19th. The technology company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.02. The firm had revenue of $5.41 million for the quarter, compared to analyst estimates of $4.72 million. iCAD had a negative net margin of 17.81% and a negative return on equity of 15.65%.
Hedge Funds Weigh In On iCAD
A number of institutional investors and hedge funds have recently bought and sold shares of ICAD. Summit Trail Advisors LLC acquired a new position in iCAD during the 4th quarter worth about $214,000. First Eagle Investment Management LLC lifted its position in shares of iCAD by 6.1% during the fourth quarter. First Eagle Investment Management LLC now owns 716,161 shares of the technology company's stock worth $1,311,000 after purchasing an additional 41,000 shares in the last quarter. Thompson Davis & CO. Inc. bought a new stake in shares of iCAD during the fourth quarter valued at approximately $31,000. PKS Advisory Services LLC acquired a new stake in shares of iCAD in the fourth quarter valued at approximately $53,000. Finally, waypoint wealth counsel raised its position in iCAD by 44.0% in the 4th quarter. waypoint wealth counsel now owns 14,400 shares of the technology company's stock worth $26,000 after purchasing an additional 4,400 shares during the last quarter. Institutional investors and hedge funds own 24.61% of the company's stock.
About iCAD
(
Get Free Report)
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Further Reading
Before you consider iCAD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iCAD wasn't on the list.
While iCAD currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
